Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis to Acquire Genomica

SAN FRANCISCO, Nov. 19 - Exelixis has agreed to acquire Genomica for a stock-for-stock transaction valued at $110 million, the companies announced on Monday.

 

The agreement, approved by both companies' board of directors, calls for South San Francisco, Calif.-based Exelixis to put in an offer for 100 percent of Genomica's outstanding common stock on or about Nov. 27, according to the companies. Following the stock buy, the companies expect to merge during the first quarter of 2002.

 

"We believe that Genomica's substantial cash and investments will significantly enhance our ability to move our drug discovery programs forward, and that their software will be an important tool to manage human data during the clinical development of our compounds," George Scangos, CEO of Exelixis, said in a statement.

 

Genomica's customers include AstraZeneca, GlaxoSmithKline, Aventis, and the National Cancer Institute. Genomica, based in Boulder, Colo., has alliances with Applied Biosystems and Celera Genomics, according to the company. As of Sept. 30, Genomica had $110.8 million in cash, cash equivalents, and investments.

 

Exelixis is a genomics-based drug discovery company with a research and development focus on comparative genomics and model genetic systems.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.